艾伯维正寻求FDA和EMA批准Rinvoq用于治疗非节段性白癜风，这是一种首创的全身性治疗。 AbbVie seeks FDA and EMA approval for Rinvoq to treat non-segmental vitiligo, a first-of-its-kind systemic treatment.

艾伯维向FDA和EMA提交了扩大Rinvoq用于治疗成人和青少年非分段性白风的申请. AbbVie has submitted applications to the FDA and EMA for expanded approval of Rinvoq to treat non-segmental vitiligo in adults and adolescents. 如果得到批准,这将是这一慢性自发性症状的首例系统药物,它会导致对称衰退。 If approved, it would be the first systemic medication for this chronic autoimmune condition, which causes symmetrical depigmentation. 该药物已被核准用于其他自发性免疫疾病,预计到2027年将产生超过110亿美元的收入。 The drug is already approved for other autoimmune diseases and is projected to generate over $11 billion in revenue by 2027.